Feasibility and Long-Term Efficacy of PEComa Treatment—20 Years of Experience

Perivascular epithelioid cell tumors (PEComas) represent a family of rare mesenchymal neoplasms, some of which are malignant. There are no specific management guidelines for PEComas, and factors correlating with the disease course are not well defined. This analysis aimed to describe the outcomes of...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine 2021-05, Vol.10 (10), p.2200
Main Authors: Sobiborowicz, Aleksandra, Świtaj, Tomasz, Teterycz, Paweł, Spałek, Mateusz J., Szumera-Ciećkiewicz, Anna, Wągrodzki, Michał, Zdzienicki, Marcin, Czarnecka, Anna M., Rutkowski, Piotr
Format: Article
Language:English
Subjects:
Clinical medicine
Disease
Females
Medical research
Metastasis
Sarcoma
Smooth muscle
Software
Survival analysis
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Perivascular epithelioid cell tumors (PEComas) represent a family of rare mesenchymal neoplasms, some of which are malignant. There are no specific management guidelines for PEComas, and factors correlating with the disease course are not well defined. This analysis aimed to describe the outcomes of PEComa patients treated radically, including those treated exclusively in the national reference sarcoma center. The secondary aim of the study was to analyze factors associated with PEComa treatment efficacy. We performed an analysis of 27 patients subsequently treated radically for PEComa between 1999 and 2019 who were in follow-up in the national sarcoma reference center. The proportional-hazards model was used to compare the risk of death. The median age at diagnosis was 45 (21–67) years, and 67% of patients were female. The median follow-up period was 68 months (95% CI: 39–101). At the time of analysis, eleven patients (40.7%) experienced progression of the disease and four (14.8%) died. Surgery in the reference sarcoma center was associated with a longer disease control (log-rank p < 0.001). The 5-year-OS rate was 88% (95% CI: 74–100) for the whole analyzed group. We concluded that PEComa treatment should be managed in reference sarcoma centers by a multidisciplinary tumor board with an experienced surgical team. Microscopically radical resection is associated with a longer disease-free survival. Patients requiring long-term follow-ups as late recurrence may be expected.
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm10102200